{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:26:36Z","timestamp":1787761596800,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,30]]},"DOI":"10.7759\/cureus.63527","type":"journal-article","created":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T20:46:33Z","timestamp":1719780393000},"source":"Crossref","is-referenced-by-count":1,"title":["Use of Chemoimmunotherapy for Locally Advanced Deficient Mismatch Repair (dMMR) Gastric Adenocarcinoma With Curative Intent: A Case Report"],"prefix":"10.7759","author":[{"given":"Beatriz","family":"Gonzalez Diez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jesus","family":"Fernandez Ace\u00f1ero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro Jesus","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Martin-Antona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham D","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al.. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006, 355:11-20. 10.1056\/NEJMoa055531","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou M","year":"2011","unstructured":"Ychou M, Boige V, Pignon JP, et al.. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011, 29:1715-21. 10.1200\/JCO.2010.33.0597","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran SE","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al.. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019, 393:1948-57. 10.1016\/S0140-6736(18)32557-1","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick F","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al.. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:1005-20. 10.1016\/j.annonc.2022.07.004","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-018-2906-9","article-title":"Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches","volume":"75","author":"Ratti M","year":"2018","unstructured":"Ratti M, Lampis A, Hahne JC, Passalacqua R, Valeri N. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cell Mol Life Sci. 2018, 75:4151-62. 10.1007\/s00018-018-2906-9","journal-title":"Cell Mol Life Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-11050-6","article-title":"Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability: systematic review and meta-analysis","volume":"29","author":"Nie RC","year":"2022","unstructured":"Nie RC, Chen GM, Yuan SQ, et al.. Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability: systematic review and meta-analysis. Ann Surg Oncol. 2022, 29:2324-31. 10.1245\/s10434-021-11050-6","journal-title":"Ann Surg Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian YY","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al.. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021, 398:27-40. 10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.6762","article-title":"Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial","volume":"3","author":"Smyth EC","year":"2017","unstructured":"Smyth EC, Wotherspoon A, Peckitt C, et al.. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017, 3:1197-203. 10.1001\/jamaoncol.2016.6762","journal-title":"JAMA Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30012-7","article-title":"Chemotherapy for resectable microsatellite instability-high gastric cancer?","volume":"21","author":"Lordick F","year":"2020","unstructured":"Lordick F. Chemotherapy for resectable microsatellite instability-high gastric cancer?. Lancet Oncol. 2020, 21:203. 10.1016\/S1470-2045(20)30012-7","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04636-y","article-title":"Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study","volume":"149","author":"Nappo F","year":"2023","unstructured":"Nappo F, Fornaro L, Pompella L, et al.. Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study. J Cancer Res Clin Oncol. 2023, 149:6601-11. 10.1007\/s00432-023-04636-y","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun JM","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, et al.. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021, 398:759-71. 10.1016\/S0140-6736(21)01234-4","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang YK","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, et al.. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022, 23:234-47. 10.1016\/S1470-2045(21)00692-6","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the Gercor Neonipiga Phase II Study","volume":"41","author":"Andr\u00e9 T","year":"2023","unstructured":"Andr\u00e9 T, Tougeron D, Piessen G, et al.. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the Gercor Neonipiga Phase II Study. J Clin Oncol. 2023, 41:255-65. 10.1200\/JCO.22.00686","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III Dante\/IKF-S633 trial","volume":"42","author":"Lorenzen S","year":"2024","unstructured":"Lorenzen S, G\u00f6tze TO, Thuss-Patience P, et al.. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III Dante\/IKF-S633 trial. J Clin Oncol. 2024, 42:410-20. 10.1200\/JCO.23.00975","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara K","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, et al.. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024, 25:212-24. 10.1016\/S1470-2045(23)00541-7","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.265","article-title":"Pathological complete response to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastro-oesophageal junction cancer: interim results of the global, phase 3 MATTERHORN study","volume":"34","author":"Oh DY","year":"2023","unstructured":"Oh DY, Janjigian YY, Al-Batran SE, et al.. Pathological complete response to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastro-oesophageal junction cancer: interim results of the global, phase 3 MATTERHORN study. Ann Oncol. 2023, 34:S1520-1. 10.1016\/j.annonc.2023.10.265","journal-title":"Ann Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the keynote-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara K","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, et al.. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the keynote-062 phase 3 randomized clinical trial. JAMA Oncol. 2020, 6:1571-80. 10.1001\/jamaoncol.2020.3370","journal-title":"JAMA Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-022-02661-8","article-title":"Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report","volume":"20","author":"Hidaka Y","year":"2022","unstructured":"Hidaka Y, Arigami T, Osako Y, et al.. Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report. World J Surg Oncol. 2022, 20:193. 10.1186\/s12957-022-02661-8","journal-title":"World J Surg Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont AM","year":"2018","unstructured":"Eggermont AM, Blank CU, Mandala M, et al.. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018, 378:1789-801. 10.1056\/NEJMoa1802357","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors","volume":"41","author":"Ludford K","year":"2023","unstructured":"Ludford K, Ho WJ, Thomas JV, et al.. Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors. J Clin Oncol. 2023, 41:2181-90. 10.1200\/JCO.22.01351","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/264143-use-of-chemoimmunotherapy-for-locally-advanced-deficient-mismatch-repair-dmmr-gastric-adenocarcinoma-with-curative-intent-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T20:46:37Z","timestamp":1719780397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/264143-use-of-chemoimmunotherapy-for-locally-advanced-deficient-mismatch-repair-dmmr-gastric-adenocarcinoma-with-curative-intent-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.63527","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,30]]}}}